News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SCYNEXIS, Inc. Presents Data Demonstrating that SCY-635 Restores the Body’s Innate Immune Response to HCV and Could be an Effective Replacement for Recombinant Interferon



11/7/2011 11:23:38 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company SCYNEXIS, Inc. today presented data demonstrating that SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection—reactivates the body’s natural defense mechanism, making it capable of inhibiting replication of the virus. The data positions SCY-635 as a potential replacement for recombinant interferon—a component of the standard of care for hepatitis C treatment that is associated with significant side effects. The data were presented in a poster session at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco. SCY-635 is currently undergoing Phase 2 studies.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES